CSIMarket
 
Cullinan Oncology Inc   (CGEM)
Other Ticker:  
 
 
Price: $16.6700 $-0.70 -4.030%
Day's High: $17.57 Week Perf: -1.94 %
Day's Low: $ 16.52 30 Day Perf: 3.73 %
Volume (M): 185 52 Wk High: $ 19.68
Volume (M$): $ 3,086 52 Wk Avg: $11.53
Open: $17.30 52 Wk Low: $7.64



 Market Capitalization (Millions $) 712
 Shares Outstanding (Millions) 43
 Employees 2
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -157
 Cash Flow (TTM) (Millions $) -178
 Capital Exp. (TTM) (Millions $) 1

Cullinan Oncology Inc

Consolidated Gems, Inc., formerly Electrum International, Inc. is a Delaware corporation that was originally incorporated in Florida as We Sell for U Corp. (“We Sell for U”) on November 12, 2007. The principal stockholder of Consolidated Gems is Power Developments Pty Ltd., an Australian corporation (“Power”), an entity majority owned by the Company’s president, which owned 82.85% of Consolidated Gems as of December 31, 2016.

In December 2008, Power acquired a 96% interest in Consolidated Gems from Edward T. Farmer and certain other stockholders. Mr. Farmer resigned as Sole Director and Officer of Electrum, Joseph Gutnick was appointed President, Chief Executive Officer and a Director and Peter Lee was appointed Chief Financial Officer and Secretary. Commencing in fiscal 2009, the Company decided to focus its business on energy opportunities.

On January 29, 2009, the Company’s Board of Directors declared a 6-for-1 stock split in the form of a stock dividend that was payable in February 2009 to stockholders of record as of February 14, 2009. The Company has accounted for this bonus issue as a stock split and accordingly, all share and per share data has been retroactively restated. An aggregate of 72,000,000 shares of common stock were issued in connection with this dividend.

On March 31, 2009, the Company’s Board of Directors declared a 2-for-1 stock split in the form of a stock dividend that was payable in August 2009 to stockholders of record as of August 12, 2009. The Company has accounted for this bonus issue as a stock split and accordingly, all share and per share data has been retroactively restated. An aggregate of 86,400,000 shares of common stock were issued in connection with this dividend.

Effective on August 12, 2009, the Company completed the reincorporation from a Florida corporation to a Delaware corporation through a merger with and into its wholly-owned subsidiary, Consolidated Gems. Each issued and outstanding share of common stock, par value US$0.0001 per share, of We Sell For U Corp., a Florida-incorporated company, was automatically converted into one issued and outstanding share of common stock, par value US$0.0001 per share, of Consolidated Gems, a Delaware-incorporated company. The number of authorized shares of capital stock was increased to five hundred twenty million (520,000,000) shares, of which five hundred million (500,000,000) shares shall be Common Stock and twenty million (20,000,000) shares shall be Preferred Stock, each with a par value of US$0.0001 per share. For purposes of the Company’s reporting status with the Securities and Exchange Commission, Consolidated Gems is deemed a successor to We Sell for U.



   Company Address: One Main Street Cambridge 2142
   Company Phone Number: 410-4650   Stock Exchange / Ticker: NASDAQ CGEM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Cullinan Oncology Receives FDA Clearance for Investigational New Drug Application for CLN-619, a Promising Antibody Targeting MICA/B in Multiple Myeloma

Published Fri, Mar 1 2024 12:00 PM UTC

Cullinan Oncology, a biopharmaceutical company focused on developing novel cancer treatments, recently announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for CLN-619, a promising antibody designed to target MICA/B in patients with relapsed or refractory multiple myeloma. This marks an i...

Clinical Study

Cullinan Oncology Initiates Phase 1 Trial of CLN-617: A Game-Changing Fusion Protein Revolutionizing Cancer Therapy

Published Thu, Dec 14 2023 9:30 PM UTC



CAMBRIDGE, Mass., Dec. 14, 2023 - Cullinan Oncology, Inc. (Nasdaq: CGEM), a leading biopharmaceutical company specializing in modality-agnostic, targeted oncology therapies, announced today the initiation of a Phase 1 clinical trial of CLN-617. This first-in-human study aims to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficac...

Cullinan Oncology Inc

Cullinan Oncology Inc Sets High Expectations for Third Quarter 2023 as CGEM Commits to Collaborative Efforts



The July to September 30, 2023 reporting season has brought forth a mixed bag of financial results for various businesses, particularly those in the Biotechnology & Pharmaceuticals sector. In a recent announcement, CGEM reported an operating shortfall of $-45.243 million for the financial three months ending September 30, 2023, which is a noticeable deterioration compared to the same quarter in the previous year. As market participants speculate about the potential revenue outlook for these companies, it is crucial to understand the implications of these results on the future of CGEM.
Operating Shortfall Woes:
CGEM's operating shortfall has worsened from $-29.766 million in the third quarter of 2022 to $-45.243 million in the same period this year. This decline indicates that CGEM has struggled to control its expenses and generate sufficient revenue during this time. The company needs to revamp its operational strategies to mitigate further losses and ensure sustainable growth.

Cullinan Oncology Inc

Prominent Biotech Firm, Cullinan Oncology Inc, Faces Soaring Business Expenses and Urgent Need for Strategic Revival

Trailing the bellwethers in the Biotechnology & Pharmaceuticals sector, a few lesser-known corporations are publishing their earnings. One such company, CGEM, recently revealed its financial results for the second quarter of 2023, reporting an operating deficit of $-37.605 million. This deficit has raised concerns among investors and analysts, prompting them to closely monitor the company's next moves.
Despite the recent downturn, the markets are hopeful that CGEM will unveil a new business strategy soon, in order to regain stability and profitability. The company's current operational conduct is not seen as an accurate reflection of its potential in the Biotechnology & Pharmaceuticals sector. As an emerging player in the industry, CGEM needs to swiftly develop and expand its business strategy while ensuring it has enough resources to effectively operate.

Cullinan Oncology Inc

Renewable Energy Innovator Cullinan Oncology Inc Faces Operating Shortfall of $62.7 Million in Q1 2023

Cullinan Oncology Inc is a biotechnology company focused on developing targeted cancer therapies. With headquarters in Cambridge, Massachusetts, USA, the company was founded in 2017 and went public in 2020. Cullinan Oncology Inc operates in the Renewable Energy Services & Equipment industry, offering innovative treatments for cancer patients. The company is known for its innovative technologies in the field of oncology and has achieved great milestones in the industry.
Recently, the Renewable Energy Services & Equipment industry consultants have begun scrutinizing the company's first quarter of 2023 performance. Presently, these consultants have monitored an operating shortfall of $-62.756 million from the CGEM, which hasn't recorded any revenue so far for the respective January to March 31, 2023, quarter. The consultants advise to frame the financial first quarter of 2023 outcome, at the prevailing instance of the business. Currently, it is easy to correlate the operating shortfall of the first quarter of 2022, which came in at $-32.657 million. On the quest to prompt the lucrative revenue sources, entities frequently undergo uncommonly choppy stints. May be one of these, is the financial span ending March 31, 2023, where the deficit has extended to $-58.141 million.
In the coming days, Cullinan Oncology Inc is expected to report its next financial results on May 15, 2023. The company's income per employee fell on a trailing twelve-month basis to $31,973,000, but the productivity of Cullinan Oncology Inc's 2 employees remained above the company average. This is a reflection of the company's continued commitment to excellence and innovation.
The Renewable Energy Services & Equipment industry has seen Cullinan Oncology Inc achieve the highest income per employee. Meanwhile, Cullinan Oncology Inc's overall ranking has deteriorated compared to the fourth quarter of 2022, from $31,973,000. This may be attributed to the unforeseeable challenges in the industry or the choppy period experienced by entities in the quest to prompt the lucrative revenue sources. However, considering the milestones achieved by Cullinan Oncology Inc as a biotechnology company, such challenges may be surmounted shortly.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com